系统性红斑狼疮患者羟氯喹剂量相关获益与风险的权衡
基于台湾全民健康保险研究数据库2010至2021年的全国性队列研究,纳入起始羟氯喹治疗的SLE患者,比较高剂量(≥400 mg/天)与低剂量(<400 mg/天)的疗效与安全性。经逆概率加权后,高剂量与较低冠心病和静脉血栓栓塞风险相关,且45岁以下患者视网膜病变风险无剂量差异,但45岁以上患者高剂量视网膜病变风险升高。
要点
- 高剂量羟氯喹与较低冠心病(HR 0.86)和静脉血栓栓塞(HR 0.40)风险相关。
- 45岁以上SLE患者高剂量羟氯喹的视网膜病变风险升高(HR 1.87)。
- 45岁以下患者视网膜病变风险无剂量相关差异。
核心结论
- 高剂量羟氯喹改善SLE疗效,降低冠心病和静脉血栓栓塞风险。
- 45岁以下患者视网膜病变风险无剂量相关差异。
- 需权衡最佳羟氯喹剂量的获益与风险。
研究设计与样本
- 全国性队列研究,数据来自台湾全民健康保险研究数据库2010至2021年。
- 纳入10岁以上、起始羟氯喹且无其他系统性自身免疫病及无历史结局的SLE患者。
- 按首次羟氯喹处方剂量分为高剂量(≥400 mg/天)和低剂量(<400 mg/天)组。
主要发现
- 逆概率加权后,高剂量与较低冠心病风险相关(HR 0.86,95%CI 0.80-0.93)。
- 高剂量与较低静脉血栓栓塞风险相关(HR 0.40,95%CI 0.33-0.49)。
- 平均随访六年,缺血性卒中、终末期肾病、恶性肿瘤及羟氯喹视网膜病变风险无剂量相关差异。
- 45岁以上SLE患者高剂量羟氯喹的视网膜病变风险升高(HR 1.87,95%CI 1.45-2.42)。
临床怎么用
- 对SLE患者可考虑高剂量羟氯喹以降低冠心病和静脉血栓栓塞风险。
- 45岁以上患者使用高剂量羟氯喹需警惕视网膜病变风险。
- 45岁以下患者高剂量与低剂量羟氯喹的视网膜病变风险无差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To weigh higher-dose hydroxychloroquine (HCQ; ≥400 mg/day) and lower-dose HCQ (<400 mg/day) for effectiveness and safety among patients with systemic lupus erythematosus (SLE). METHODS: This nationwide study retrieved data from Taiwan's National Health Insurance Research Database from 2010 to 2021. We included patients with SLE aged over 10 years and initiating HCQ who had no other systemic autoimmune disease at baseline and no historical outcomes of interest. Patients were classified into higher-dose (≥400 mg/day) or lower-dose (<400 mg/day) treatment strategies based on the dosage of their first HCQ prescription. The outcomes were coronary artery disease (CAD), ischemic stroke, venous thromboembolism (VTE), end-stage renal disease, malignancy, and HCQ retinopathy. RESULTS: Eight hundred seventy-eight (3.77%) patients taking higher-dose HCQ and 22,405 (96.22%) taking lower-dose HCQ were included. After inverse probability weighting, higher-dose HCQ was associated with lower risks of CAD (hazard ratio [HR] 0.86, 95% confidence interval [CI] 0.80-0.93) and VTE (HR 0.40, 95% CI 0.33-0.49). We found no dose-related difference in the risk of ischemic stroke, end-stage renal disease, malignancy, and HCQ retinopathy through a mean follow-up of six years, except for the HCQ retinopathy among patients with SLE aged over 45 years (HR 1.87, 95% CI 1.45-2.42). CONCLUSION: For patients with SLE, higher-dose HCQ improves effectiveness, with reduced risks of CAD and VTE. There was no dose-related difference in the risk of HCQ retinopathy for patients with SLE aged younger than 45 years. Our study emphasizes the need for weighing the benefits and risks of optimal HCQ dosage in managing SLE.
引用
- Li BM, Hung JH, Yang PC, et al. Weighing Dose-Related Benefits and Risks of Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2026. PMID: 41423344. doi:10.1002/art.70022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。